Company intelligence / Profile preview

GBP Life Science Holdings

Plaengyao, Chachoengsao, Thailand

Ownership: Private
Development stage: Other

Overview

GBP supplies WHO and TGA (Australia) prequalified live attenuated and recombinant vaccines for Japanese encephalitis, measles, hepatitis B, rabies, and other diseases, with its products included in national immunization plans and international markets, including Australia and 14+ other countries

Therapeutic areas: Women's HealthInfectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Partnerships

Government Pharmaceutical Organization (Thai state entity)Substipharm BiologicsSiam BioscienceSanofi Pasteur (historical)

Beyond the preview

Go deeper on GBP Life Science Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GBP Life Science Holdings.

Explore the full profile